Breaking news

Novartis Acquires Blackstone’s Anthos Therapeutics For Up To $3.1 Billion To Strengthen Cardiovascular Portfolio

by THEFUTURE.TEAM
February 11, 2025

Swiss pharmaceutical giant Novartis has struck a deal to acquire Anthos Therapeutics, a biopharma company majority-owned by Blackstone’s drug development arm, for up to $3.1 billion. The acquisition is aimed at bolstering Novartis’ presence in the cardiovascular sector, a key focus for the company as its blockbuster heart failure drug Entresto faces patent expiration this year.

Founded in 2019 by Blackstone’s Life Sciences division and Novartis, Anthos was created to develop abelacimab, a promising treatment designed to prevent strokes and prevent recurring blood clots. This transaction underscores Novartis’ commitment to cardiovascular treatments, which is one of five critical therapeutic areas the company is prioritizing.

The deal, which is expected to close by mid-2025, marks a significant step in the evolving partnership between a major pharmaceutical company and private equity, a model that has gained traction in the industry. Novartis will pay an initial $925 million, with potential additional payments up to $2.15 billion, contingent on the successful development of the therapy.

This marks the largest sale of a majority-owned company by Blackstone’s Life Sciences division to date. In December 2023, Blackstone was exploring the sale of Anthos, and the current deal brings the partnership to a close.

Abelacimab is part of a new class of anticoagulants known as factor XI inhibitors, designed to potentially replace established blood thinners like Eliquis (Bristol Myers-Squibb and Pfizer) and Xarelto (Johnson & Johnson and Bayer), both of which are billion-dollar sellers. Other major companies in the factor XI race include Bristol-Myers Squibb and Johnson & Johnson, who are advancing a similar drug candidate, as well as Merck & Co, which is progressing with a mid-stage development candidate. Bayer, meanwhile, faced a setback in 2023 with its factor XI drug.

Nicholas Galakatos, Chairman of Anthos’ board and Global Head of Blackstone Life Sciences expressed pride in the firm’s role in launching and growing Anthos, adding, “We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab for millions of patients at risk of strokes.”

Anthos is currently conducting multiple Phase 3 clinical trials, with data expected in the second half of 2026. While Novartis holds a small minority equity stake in Anthos, the company has not disclosed the exact size of this investment.

Donatella Versace Steps Down After 30 Years At The Helm of Fashion Empire

by THEFUTURE.TEAM
March 14, 2025

After nearly three decades steering the iconic Versace brand, Donatella Versace is stepping down from her role as head of the fashion house. The 69-year-old Italian designer, who inherited the reins from her late brother, Gianni, following his tragic murder in 1997, will remain with the company as its Chief Brand Ambassador. She is set to pass the creative torch to Dario Vitale, the former design and image director of Miu Miu, who will take on the position of Chief Creative Officer.

In her Instagram announcement, Donatella shared her thoughts: “Championing the next generation of designers has always been important to me,” she wrote, expressing her excitement for Vitale’s appointment. “I am thrilled that Dario Vitale will be joining us, and I am eager to see Versace through new eyes.”

While her new role shifts focus, Donatella’s deep connection to Versace remains unchanged. “Versace is in my DNA and always in my heart,” she declared. Donatella’s stewardship has firmly cemented the brand as a staple in the luxury fashion industry, with designs worn by global superstars like Dua Lipa, Angelina Jolie, and Sabrina Carpenter.

In a heartfelt reflection, Donatella expressed her gratitude: “It has been the greatest honour of my life to carry on my brother Gianni’s legacy. He was the true genius, but I hope I have some of his spirit and tenacity.” Despite her transition, she reaffirmed her commitment to the brand’s future, adding: “I will remain Versace’s most passionate supporter.”

The announcement was met with a wave of tributes from the fashion world. Celebrities like actor Damian Hurley, singer Sabrina Carpenter, and model Iris Law shared their admiration for the designer’s contribution to the industry. “We love you forever,” Hurley commented, while Carpenter called her “one and only,” and Law posted, “Love you so much.”

This shake-up in leadership comes as speculation mounts that Prada Group may be eyeing a potential acquisition of Versace from its current owner, Capri Holdings, which purchased the luxury brand for €2 billion in 2018. As Donatella steps into her new role, the future of Versace remains closely watched by both fans and industry insiders.

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter